☆ 4.7 Meeting Abstract

Checkmate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo) plus ipilimumab (Ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 35, Issue 4, Pages -

Publisher

AMER SOC CLINICAL ONCOLOGY

DOI: 10.1200/JCO.2017.35.4_suppl.TPS213

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)

Hussein A. Tawbi, Peter A. Forsyth, F. Stephen Hodi, Christopher D. Lao, Stergios J. Moschos, Omid Hamid, Michael B. Atkins, Karl Lewis, Reena P. Thomas, John A. Glaspy, Sekwon Jang, Alain P. Algazi, Nikhil Khushalani, Michael A. Postow, Anna C. Pavlick, Marc S. Ernstoff, David A. Reardon, Igor Puzanov, Ragini R. Kudchadkar, Ahmad A. Tarhini, Anne Sumbul, Jasmine Rizzo, Kim A. Margolin

Summary: The combination of nivolumab and ipilimumab shows durable clinical benefit for asymptomatic patients with melanoma brain metastases, but has limited activity in patients with neurological symptoms and/or requiring corticosteroids.

NEURO-ONCOLOGY (2021)

Add to Collection

Article Oncology

First-line nivolumab plus ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients

K. J. O'Byrne, K. H. Lee, S-W Kim, K. Park, M. Nishio, H. Sakai, Y. Ohe, T. Fukuhara, J-H Kang, H. Daga, C-J Yu, K. Hotta, H. Tanaka, M. Takeda, T. Yokoyama, F. E. Nathan, J-S Lee

Summary: Nivolumab plus ipilimumab provides durable long-term efficacy benefits as first-line treatment in the Asian subpopulation with advanced non-small cell lung cancer (NSCLC), regardless of tumor PD-L1 expression, particularly in Japanese patients.

ESMO OPEN (2022)

Add to Collection

Article Oncology

Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial

Andrea B. Apolo, Thomas Powles, Bernard Escudier, Mauricio Burotto, Joshua Zhang, Burcin Simsek, Christian Scheffold, Robert J. Motzer, Toni K. Choueiri

Summary: This study analyzed the clinical activity of the nivolumab plus ipilimumab plus cabozantinib triplet combination in previously untreated aRCC patients, showing a certain efficacy but the need for monitoring overlapping toxicities.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1

Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, Michael Schenker, Clarisse Audigier-Valette, Bogdan Zurawski, Helena Linardou, Gregory A. Otterson, Pamela Salman, Makoto Nishio, Emmanuel de la Mora Jimenez, Krysztof Lesniewski-Kmak, Istvan Albert, Samreen Ahmed, Konstantinos Syrigos, John R. Penrod, Yong Yuan, Steven Blum, Faith E. Nathan, Xiaowu Sun, Alejandro Moreno-Koehler, Fiona Taylor, Kenneth John O'Byrne

Summary: The study demonstrated that in treatment-naive patients with advanced NSCLC, nivolumab plus ipilimumab showed delayed deterioration and numerical improvement in symptoms and health-related quality of life compared to chemotherapy.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Article Oncology

Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817

Luis G. Paz-Ares, Tudor-Eliade Ciuleanu, Adam Pluzanski, Jong-Seok Lee, Justin F. Gainor, Gregory A. Otterson, Clarisse Audigier-Valette, Neal Ready, Michael Schenker, Helena Linardou, Reyes Bernabe Caro, Mariano Provencio, Bogdan Zurawski, Ki Hyeong Lee, Sang-We Kim, Claudia Caserta, Suresh S. Ramalingam, David R. Spigel, Julie R. Brahmer, Martin Reck, Kenneth J. O'Byrne, Nicolas Girard, Sanjay Popat, Solange Peters, Arteid Memaj, Faith Nathan, Nivedita Aanur, Hossein Borghaei

Summary: This study assessed the safety and efficacy of first-line nivolumab plus ipilimumab (NIVO+IPI) in a large population of patients with metastatic non-small cell lung cancer (NSCLC). The findings showed that the treatment had relatively lower safety in older patients, but discontinuation did not reduce long-term survival in responders.

JOURNAL OF THORACIC ONCOLOGY (2023)

Add to Collection

Article Oncology

Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4

Oscar Krijgsman, Kristel Kemper, Julia Boshuizen, David W. Vredevoogd, Elisa A. Rozeman, Sofia Ibanez Molero, Beaunelle de Bruijn, Paulien Cornelissen-Steijger, Aida Shahrabi, Martin Del Castillo Velasco-Herrera, Ji-Ying Song, Maarten A. Ligtenberg, Roelof J. C. Kluin, Thomas Kuilman, Petra Ross-Macdonald, John B. A. G. Haanen, David J. Adams, Christian U. Blank, Daniel S. Peeper

Summary: This study used different signatures to predict the response and benefits of anti-PD-1 and anti-CTLA-4 treatments in melanoma patients, identifying which patients need combination immune checkpoint blockade therapy.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis

H. Borghaei, T. -E. Ciuleanu, J. -S Lee, A. Pluzanski, R. Bernabe Caro, M. Gutierrez, Y. Ohe, M. Nishio, J. Goldman, N. Ready, D. R. Spigel, S. S. Ramalingam, L. G. Paz-Ares, J. F. Gainor, S. Ahmed, M. Reck, M. Maio, K. J. O'Byrne, A. Memaj, F. Nathan, P. Tran, M. D. Hellmann, J. R. Brahmer

Summary: First-line nivolumab plus ipilimumab treatment in advanced NSCLC can prolong survival and have significant clinical benefits, with tumor response affecting survival.

ANNALS OF ONCOLOGY (2023)

Add to Collection

Review Oncology

Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis

Huihui Jiang, Aiqun Xu, Wanli Xia, Xingyuan Xia, Pulin Li, Binbin Zhang, Ke Zhu, Sijing Zhou, Ran Wang

Summary: Through comprehensive analysis, lung cancer patients treated with immunotherapy showed better overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) compared to those receiving chemotherapy. Whether used alone or in combination, immunotherapy demonstrated more clinically meaningful survival benefits.

CANCER CELL INTERNATIONAL (2021)

Add to Collection

Article Oncology

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920

Hamid Emamekhoo, Mark R. Olsen, Bradley C. Carthon, Alexandra Drakaki, Ivor J. Percent, Ana M. Molina, Daniel C. Cho, Johanna C. Bendell, Lucio N. Gordan, Arash Rezazadeh Kalebasty, Daniel J. George, Thomas E. Hutson, Edward R. Arrowsmith, Joshua Zhang, Jesus Zoco, Jennifer L. Johansen, David K. Leung, Scott S. Tykodi

Summary: The study aimed to evaluate the safety and efficacy of Nivolumab plus Ipilimumab combination therapy in patients with previously untreated advanced renal cell carcinoma and asymptomatic brain metastases. Results showed encouraging antitumor activity of the drug combination with no new safety signals.

CANCER (2022)

Add to Collection

Article Oncology

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

Karim Fizazi, Margitta Retz, Daniel P. Petrylak, Jeffrey C. Goh, Jose Perez-Gracia, Louis Lacombe, Stefanie Zschabitz, Mauricio Burotto, Hakim Mahammedi, Gwenaelle Gravis, Diogo Assed Bastos, Steven L. McCune, Juan Carlos Vazquez Limon, Edmond M. Kwan, Daniel Castellano, Aude Flechon, Fred Saad, Marc-Oliver Grimm, David R. Shaffer, Andrew J. Armstrong, Prabhu Bhagavatheeswaran, Neha P. Amin, Keziban Unsal-Kacmaz, Xuya Wang, Jun Li, Andrea Loehr, Russell K. Pachynski

Summary: The study showed that nivolumab plus rucaparib is effective in patients with HRD-positive postchemotherapy or chemotherapy-naive mCRPC, especially those with BACA1/2 mutations. Safety profile was as expected with no new signals identified. It remains unclear whether the addition of nivolumab provides incremental improvements over rucaparib alone.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Oncology

First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis

Tianshu Liu, Yuxian Bai, Xiaoyan Lin, Wei Li, Jufeng Wang, Xiaochun Zhang, Hongming Pan, Chunmei Bai, Li Bai, Ying Cheng, Jingdong Zhang, Haijun Zhong, Yi Ba, Wenwei Hu, Ruihua Xu, Weijian Guo, Shukui Qin, Nong Yang, Jianwei Lu, Kohei Shitara, Ming Lei, Mingshun Li, Nicole Bao, Tian Chen, Lin Shen

Summary: Chinese patients in the global CheckMate 649 study showed improved efficacy and safety with nivolumab plus chemotherapy as first-line treatment for GC/GEJC/EAC.

INTERNATIONAL JOURNAL OF CANCER (2023)

Add to Collection

Article Pharmacology & Pharmacy

Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer

Xuezhi Hao, Aizong Shen, Bin Wu

Summary: The cost-effectiveness analysis of nivolumab plus ipilimumab for advanced non-small cell lung cancer showed that it is a cost-effective option in the United States but not in China. Sensitivity analyses confirmed the robustness of the results.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Oncology

Temozolomide combined with ipilimumab plus nivolumab enhances T cell killing of MGMT-expressing, MSS colorectal cancer cells

Zenovia Gonzalez, Lindsey Carlsen, Wafik S. El-Deiry

Summary: Colorectal cancer is the third most diagnosed and deadliest cancer globally. Most metastatic colorectal cancer patients have microsatellite stable tumors that do not respond to immune checkpoint inhibitors. The results of the 2022 MAYA clinical trial suggest that combining the DNA-damaging agent temozolomide with immune checkpoint inhibitors can sensitize certain colorectal cancer patients to treatment. The study aimed to determine the effects of adding immune checkpoint inhibitors to temozolomide on colorectal cancer cells and the role of MGMT in this response.

AMERICAN JOURNAL OF CANCER RESEARCH (2023)

Add to Collection

Article Medicine, General & Internal

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian, Kohei Shitara, Markus Moehler, Marcelo Garrido, Pamela Salman, Lin Shen, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, Arinilda Campos Bragagnoli, Tianshu Liu, Michael Schenker, Patricio Yanez, Mustapha Tehfe, Ruben Kowalyszyn, Michalis V. Karamouzis, Ricardo Bruges, Thomas Zander, Roberto Pazo-Cid, Erika Hitre, Kynan Feeney, James M. Cleary, Valerie Poulart, Dana Cullen, Ming Lei, Hong Xiao, Kaoru Kondo, Mingshun Li, Jaffer A. Ajani

Summary: Nivolumab plus chemotherapy showed superior overall survival and progression-free survival compared to chemotherapy alone in previously untreated patients with advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma, indicating it as a new standard first-line treatment option with acceptable safety profile.

LANCET (2021)

Add to Collection

Article Oncology

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)

Jeffrey S. Weber, Dirk Schadendorf, Michele Del Vecchio, James Larkin, Victoria Atkinson, Michael Schenker, Jacopo Pigozzo, Helen Gogas, Stephane Dalle, Nicolas Meyer, Paolo A. Ascierto, Shahneen Sandhu, Thomas Eigentler, Ralf Gutzmer, Jessica C. Hassel, Caroline Robert, Matteo S. Carlino, Anna Maria Di Giacomo, Marcus O. Butler, Eva Munoz-Couselo, Michael P. Brown, Piotr Rutkowski, Andrew Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis de la Cruz-Merino, Andrew Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis De La Cruz-Merino, Andre van der Westhuizen, Alexander M. Menzies, Sandra Re, Tuba Bas, Veerle de Pril, Julia Braverman, Daniel J. Tenney, Hao Tang, Georgina Long

Summary: The CheckMate 915 trial compared adjuvant nivolumab plus ipilimumab with nivolumab alone in patients with resected melanoma. The study found that there was no significant difference in recurrence-free survival between the two treatment groups.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Pharmacology & Pharmacy

Is there still a place for radiotherapy in gastric cancer?

Irene Y. Chong, Ian Chau

Summary: Stomach cancer is a global health problem that requires multimodality treatment for locally advanced cases. The use of chemoradiotherapy after D2 gastrectomy has not been supported by the best evidence so far. Ongoing trials with translational endpoints will provide important guidance for the use of chemoradiotherapy in the neoadjuvant setting. Radiotherapy can effectively alleviate symptoms of advanced gastric cancer and Stereotactic Body Radiotherapy shows promise in controlling oligometastatic liver disease in some patients.

CURRENT OPINION IN PHARMACOLOGY (2023)

Add to Collection

Article Oncology

SARS-CoV-2 Vaccine Immunogenicity in Patients with Gastrointestinal Cancer Receiving Systemic Anti-Cancer Therapy

David K. Lau, Maria Aresu, Timothy Planche, Amina Tran, Retchel Lazaro-Alcausi, Julie Duncan, Shannon Kidd, Susan Cromarty, Ruwaida Begum, Isma Rana, Su Li, Ali Abdulnabi Mohamed, Irene Monahan, David J. Clark, Nicholas Eckersley, Henry M. Staines, Elisabetta Groppelli, Sanjeev Krishna, Martin Mayora-Neto, Nigel Temperton, Charlotte Fribbens, David Watkins, Naureen Starling, Ian Chau, David Cunningham, Sheela Rao

Summary: The study evaluated the prevalence of neutralizing antibodies in 152 gastrointestinal cancer patients receiving chemotherapy after SARS-CoV-2 vaccination, finding that despite the immunosuppressive effects of chemotherapy, two doses of vaccines can still induce a protective immune response in patients undergoing treatment.

ONCOLOGIST (2023)

Add to Collection

Article Oncology

ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C)

Susanna Slater, Annette Bryant, Hsiang-Chi Chen, Ruwaida Begum, Isma Rana, Maria Aresu, Clare Peckitt, Oleg Zhitkov, Retchel Lazaro-Alcausi, Victoria Borja, Rachel Powell, David Lowery, Michael Hubank, Thereasa Rich, Gayathri Anandappa, Ian Chau, Naureen Starling, David Cunningham

Summary: This study aims to determine whether a de-escalation strategy using ctDNA to guide adjuvant chemotherapy is as effective as standard of care chemotherapy in patients with resected colorectal cancer. The primary endpoint is the difference in disease-free survival at 3 years between the trial arms. The study has the potential to reduce unnecessary chemotherapy and associated toxicity.

BMC CANCER (2023)

Add to Collection

Article Oncology

Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre

David K. Lau, Caroline Fong, Faten Arouri, Lillian Cortez, Hannah Katifi, Reyes Gonzalez-Exposito, Muhammad Bilal Razzaq, Su Li, Aislinn Macklin-Doherty, Monica Arenas Hernandez, Michael Hubank, Charlotte Fribbens, David Watkins, Sheela Rao, Ian Chau, David Cunningham, Naureen Starling

Summary: A retrospective study was conducted in a high volume cancer center in London to evaluate the impact of implementing DPYD variant testing for gastrointestinal cancer patients. The results showed that DPYD genotype testing prior to fluoropyrimidine chemotherapy ensured patient safety and the incidence of adverse events was similar to wild-type carriers.

BMC CANCER (2023)

Add to Collection

Article Oncology

Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trials

Avani Athauda, Matthew Nankivell, Rupert Langer, Susan Pritchard, Ruth E. Langley, Katharina von Loga, Naureen Starling, Ian Chau, David Cunningham, Heike I. Grabsch

Summary: No definitive largescale data exist evaluating the role of pathologically defined regression changes within the primary tumour and lymph nodes (LN) of resected oesophagogastric (OG) adenocarcinoma following neoadjuvant chemotherapy and the impact on survival.

BRITISH JOURNAL OF CANCER (2023)

Add to Collection

Article Oncology

Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02) : primary and updated analyses from a single-arm, phase 2

Eric Van Cutsem, Maria di Bartolomeo, Elizabeth Smyth, Ian Chau, Haeseong Park, Salvatore Siena, Sara Lonardi, Zev A. Wainberg, Jaffer Ajani, Joseph Chao, Yelena Janjigian, Amy Qin, Jasmeet Singh, Ferdous Barlaskar, Yoshinori Kawaguchi, Geoffrey Ku

Summary: The DESTINY-Gastric02 trial is a phase 2 study evaluating the efficacy of trastuzumab deruxtecan in HER2-positive advanced gastric and gastro-oesophageal junction cancer. The results demonstrate clinically meaningful response rates, supporting its use as second-line therapy for these patients.

LANCET ONCOLOGY (2023)

Add to Collection

Letter Oncology

A retrospective study of MYC rearranged diffuse large B-cell lymphoma in the context of the new WHO and ICC classifications

Dima El-Sharkawi, Amit Sud, Catherine Prodger, Jahanzaib Khwaja, Rohan Shotton, Brian Hanley, Victoria Peacock, Ying Ying Peng, Anita Arasaretnam, Sarkhara Sharma, Frances Aldridge, Bhupinder Sharma, Andrew Wotherspoon, Betty Cheung, Corinne De Lord, Rosalynd Johnston, Shireen Kassam, Ruth Pettengel, Kim Linton, Paul Greaves, Lucy Cook, Kikkeri N. Naresh, Kate Cwynarski, Toby A. Eyre, Ian Chau, David Cunningham, Sunil Iyengar

BLOOD CANCER JOURNAL (2023)

Add to Collection

Article Oncology

Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study

Do-Youn Oh, Maria Alsina Maqueda, David I. Quinn, Peter J. O'Dwyer, Ian Chau, Sun Young Kim, Ignacio Duran, Daniel Castellano, Jordan Berlin, Begona Mellado, Stephen K. Williamson, Keun-Wook Lee, Francisca Marti, Paul Mathew, Muhammad Wasif Saif, Ding Wang, Elizabeth Chong, Jacqueline Hilger-Rolfe, James P. Dean, Hendrik-Tobias Arkenau

Summary: This study evaluated the safety and efficacy of Ibrutinib combined with companion drugs for RCC, GC, and CRC, but did not observe clinically significant increases in efficacy compared to historical controls.

BMC CANCER (2023)

Add to Collection

Editorial Material Oncology

Pembrolizumab as a first-line treatment for advanced gastric cancer

Ian Chau

LANCET ONCOLOGY (2023)

Add to Collection

Meeting Abstract Oncology

Clonal mutation burden and evolutionary dynamics analysis in metastatic gastro-esophageal adenocarcinoma (GEA) by error corrected whole-exome circulating tumor DNA sequencing

Neil McCafferty, Caroline Fong, Louise J. Barber, Andrew Woolston, Dimitrios Kleftogiannis, Taqia Rana, Susan Cromarty, Shannon Kidd, Ruwaida Begum, Ian Chau, Naureen Starling, David Cunningham, Marco Gerlinger

CANCER RESEARCH (2023)

Add to Collection

Meeting Abstract Oncology

Circulating tumor DNA for recurrence prediction and efficacy analysis in the ICONIC trial of peri-operative FLOT and avelumab (PD-L1) in localized esophago-gastric adenocarcinoma

Marco Gerlinger, Anderley Gordon, Louise J. Barber, Georgios Laliotis, Avani Athauda, Benjamin Challoner, Andrew Woolston, Sonia Mansukhani, Matt Dunstan, Nikoletta Petrou, Komel Khabra, Retchel Lazaro-Alcausi, Richard Crux, Victoria Borja, Ruwaida Begum, Isma Rana, Charuta Palsuledesai, Meenakshi Malhotra, Minetta Liu, Adham Jurdi, Shruti Sharma, Sheela Rao, Sacheen Kumar, David Cunningham, Ian Chau, Naureen Starling, M. Asif Chaudry

CANCER RESEARCH (2023)

Add to Collection

Article Oncology

MicroRNAs as biomarkers for trastuzumab-based therapy in HER2-positive advanced oesophago-gastric cancer patients

Hazel Lote, Florentia Mousoullou, George Vlachogiannis, Andrea Lampis, Laura Satchwell, Clare Peckitt, Caroline Fong, Ruwaida Begum, Shannon Kidd, Susan Cromarty, Anderley Gordon, Charlotte Fribbens, Sheela Rao, Naureen Starling, Ian Chau, David Cunningham, Nicola Valeri

Summary: This study identified miR-148a-3p as a potential biomarker for trastuzumab-based therapy in HER2-positive oesophago-gastric cancer patients. The results showed that the expression level of miR-148a-3p is associated with patient survival and progression rates.

FRONTIERS IN ONCOLOGY (2023)

Add to Collection

Meeting Abstract Biophysics

T DEPLETE ALLOGENEIC HAEMATOPOETIC STEM CELL TRANSPLANT FOR RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA: HIGH RATES OF RESPONSE POST TRANSPLANT EVEN IN THE SETTING OF PRE TRANSPLANT RESIDUAL DISEASE

Shima Ismail, Farheen Mir, Chloe Anthias, Sandra Easdale, Mike Potter, Mark Ethell, Carlos Arias, Bhupinder Sharma, David Cunningham, Ian Chau, Sunil Iyengar, Dima El-Sharkawi, Emma Nicholson

BONE MARROW TRANSPLANTATION (2023)

Add to Collection

Meeting Abstract Oncology

MicroRNAs (miRs) as biomarkers of resistance to trastuzumab in HER2-positive oesophago-gastric cancer: Sub-study within the Planning Treatment for OesophagoGastric Cancer-A Randomised Maintenance Therapy Trial (PLATFORM).

Hazel Lote, Florentia Mousoullou, George Vlachogiannis, Caroline Fong, Laura Satchwell, Clare Peckitt, Ruwaida Begum, Shannon Kidd, Susan Cromarty, Anderley Gordon, Charlotte Victoria Fribbens, David J. Watkins, Sheela Rao, Ian Chau, Naureen Starling, David Cunningham, Nicola Valeri

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Meeting Abstract Oncology

NET-02 final results: A randomised, phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (PD-EP-NEC).

Mairead Geraldine McNamara, Jayne Swain, Zoe Craig, Rohini Sharma, Olusola Olusesan Faluyi, Jonathan Wadsley, Carys Morgan, Lucy R. Wall, Ian Chau, Nick Reed, Debashis Sarker, Jane Margetts, Daniel Krell, Judith Cave, Sothi Sharmila, Alan Anthoney, Alkesh Patel, Angela Lamarca, Richard Hubner, Juan W. Valle

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.